Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Janssen And Johnson & Johnson Innovation Announce First-Of-Its-Kind Inflammatory Bowel Disease Research Alliance With The Icahn



     Janssen And Johnson & Johnson Innovation Announce First-Of-Its-Kind
Inflammatory Bowel Disease Research Alliance With The Icahn School Of Medicine
                                At Mount Sinai

-- Industry and Academic Teams Converge to Focus on the Discovery of Next
Generation Therapeutic Solutions for the More Than Five Million People
Affected by Inflammatory Bowel Disease Worldwide1 --

PR Newswire

SPRING HOUSE, Pa. and CAMBRIDGE, Mass., June 27, 2013

SPRING HOUSE, Pa. and CAMBRIDGE, Mass., June 27, 2013 /PRNewswire/ -- Janssen
Biotech, Inc. ("Janssen") and Johnson & Johnson Innovation announced today the
establishment of a research alliance with The Icahn School of Medicine at
Mount Sinai ("Mount Sinai") to advance the scientific understanding of
inflammatory bowel disease (IBD) and the discovery of next generation
therapeutic solutions.  Scientists from the Janssen Immunology Therapeutic
Area and researchers from Mount Sinai will work in partnership to investigate
disease triggers, identify new opportunities for therapeutic interventions and
establish diagnostics to facilitate precision medicine and predictive
biomarkers.  The first-of-its-kind industry and academic partnership brings
together Janssen research and development capabilities with an early-stage
life science investment through the Johnson & Johnson Innovation center in
Boston and Mount Sinai's expertise in computational biology, and clinical and
translational research in IBD. 

"The collaboration with Mount Sinai underscores a shared commitment to further
understand inflammatory bowel disease biology and advance patient care through
the discovery of novel therapeutic solutions," said Miguel S. Barbosa, Ph.D.,
Vice President, Head of Immunology Research & Scientific Partnership Strategy,
Janssen Research & Development, LLC.  "By bringing together two excellent
scientific teams with a shared long-term vision to improve the health of
individuals living with IBD, we will harness the joint expertise and
capabilities to deepen the scientific understanding of the disease and deliver
future innovative medicines and co-diagnostics."

"Research alliances such as these, managed by the team at Mount Sinai
Innovation Partners, allow us to develop, patent, license, and translate
laboratory breakthroughs into clinical applications," said Dennis Charney,
M.D., Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount
Sinai and Executive Vice President for Academic Affairs of The Mount Sinai
Medical Center.  "The strength of Janssen for therapies in immune-related
diseases is an ideal match for our own clinical and research expertise in
inflammatory bowel disease."

The collaboration will focus on building a Molecular Interaction Network of
Disease (MIND) in IBD with the breadth and depth to yield high confidence
therapeutic hypotheses to be tested in vitro and in vivo.  Using preclinical
models, clinical study data and patient samples, a dedicated group of Janssen
and Mount Sinai researchers, computational biologists and translational
medicine scientists will develop clinical methodologies to test hypotheses and
identify potential therapeutic candidates. 

This unique industry and academic research alliance brings together scientific
and institutional resources from Mount Sinai, Janssen and Johnson & Johnson
Innovation representing each organization's deep commitment and investment in
transforming the treatment of IBD.  Detailed terms of the agreement are not
being disclosed, but a successful collaboration may represent a multi-million
dollar commitment each year over a four-year period in the pursuit of next
generation therapeutic solutions for IBD.     

"The research alliance with Mount Sinai is representative of the Johnson &
Johnson Innovation strategy—catalyze early-stage innovation through a regional
network of collaborators to advance breakthrough science into new healthcare
solutions," said Robert Urban, Ph.D., Head of the Johnson & Johnson Innovation
center in Boston.  "By connecting with leading experts who are based in
universities, academic centers or biotechnology companies, we are eager to
help these researchers bring their discoveries into the lives of patients
suffering from high unmet medical needs, like Crohn's disease and ulcerative
colitis."

As many as 1.4 million people in the United States and more than five million
people worldwide are affected by IBD, chronic, immune-mediated digestive
diseases that include Crohn's disease and ulcerative colitis (UC).^1  The
symptoms of Crohn's disease and UC can be severe and progress to the need for
surgical intervention.  Although progress has been made in research and
treatment over the years, researchers do not know what causes IBD.^2

About the Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our time,
including oncology (e.g., multiple myeloma and prostate cancer), immunology
(e.g., rheumatoid arthritis, IBD and psoriasis), neuroscience (e.g.,
schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS,
Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases
(e.g., diabetes).

Driven by our commitment to patients, we develop sustainable, integrated
healthcare solutions by working side-by-side with healthcare stakeholders,
based on partnerships of trust and transparency.  To learn more, visit
www.janssen.com. 

About Johnson & Johnson Innovation
The Boston Innovation Center is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Corporation.  Johnson & Johnson
Innovation focuses on accelerating early innovation and enhancing
opportunities for collaboration and investment across Johnson & Johnson's
global healthcare businesses.  Johnson & Johnson Innovation provides
scientists, entrepreneurs and emerging companies focused on early-stage
opportunities a one-stop access to science and technology experts who can
facilitate collaborations across the pharmaceutical, medical device and
diagnostics and consumer companies of Johnson & Johnson.  Johnson & Johnson
Innovation includes local deal-making capabilities with the flexibility to
adapt deal structures to match early-stage opportunities and establish novel
collaborations that speed development of those innovations to solve unmet
needs in patients. More information can be found here: www.jnjinnovation.com.

Forward-looking Statements
(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events.  If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Janssen Biotech,
Inc., any of the other Janssen Pharmaceutical Companies, Johnson & Johnson
Finance Corporation and/or Johnson & Johnson.  Risks and uncertainties
include, but are not limited to, general industry conditions and competition;
economic factors, such as interest rate and currency exchange rate
fluctuations; technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; changes in behavior and
spending patterns or financial distress of purchasers of health care products
and services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment; and
increased scrutiny of the health care industry by government agencies.  A
further list and description of these risks, uncertainties and other factors
can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well
as subsequent filings, are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson.  The Janssen Pharmaceutical Companies, Johnson
& Johnson Finance Corporation and Johnson & Johnson do not undertake to update
any forward-looking statements as a result of new information or future events
or developments.)

References:

1.     About Us. World IBD Day. Available at:
http://www.worldibdday.org/aboutus.html. April 2013.
2.     World IBD Day. About Us. Available at: http://ibdday.bvsalud.org/.
Accessed April 2013. 

SOURCE Janssen Biotech, Inc.

Website: http://www.janssen.com
Contact: Media Contact, Brian Kenney, Office: 215-628-7010, Mobile:
215-620-0111, or Investors: Louise Mehrotra, Johnson & Johnson, Office:
732-524-6491, or Stan Panasewicz, Johnson & Johnson, Office: 732-524-2524
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement